While some patches claim to use DMSO or iontophoresis technology for enhanced absorption, zero bioavailability evidence exists for commercially available GLP-1 patches
Timblin GA, Tharp KM, Ford B, Winchester JM, Wang J, Zhu S, Khan RI, Louie SK, Iavarone AT, Ten Hoeve J, Nomura DK, Stahl A, Saijo K (2021) Mitohormesis reprogrammes macrophage metabolism to enforce tolerance
3.3 Metabolic modulation and immunomodulatory effects The close relationship between BMI, metabolic dysfunction, and immune activation has important implications for the potential use of GLP-1Ras in obese patients with PsA
GLP-1 Persistence is Challenging, But Critical to Outcomes In 2025, we saw a lot of data showing that GLP-1 patients often stop taking their medications before reaching their goals